BMO Capital analyst Evan Seigerman lowered the firm’s price target on Regeneron to $960 from $1,040 and keeps an Outperform rating on the shares ahead of the Q2 results. A quick resolution of the 8mg aflibercept CRL could help investors regain confidence in the story, the analyst says in a research note. While the firm says the Eylea CRL delays commercialization, it is unlikely that it will prevent eventual approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron price target lowered to $900 from $935 at Guggenheim
- Alnylam announces updated interim results from ALN-APP study
- Regeneron 483 issues might not require reinspection, says Morgan Stanley
- Regeneron gets FDA orphan drug designation for cemdisiran
- Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023